Literature DB >> 6603316

Specificity of anti-nucleoside antibodies in systemic lupus erythematosus.

R H Weisbart, R A Garrett, M R Liebling, E V Barnett, H E Paulus, D H Katz.   

Abstract

The titer of IgG antinucleoside antibodies in the sera of 162 individuals was determined by an enzyme-linked immunosorbent assay. The nucleosides used in the assay were adenosine, cytidine, guanosine, and thymine-riboside conjugated to human serum albumin. The specificity of IgG antinucleoside antibodies was indicated by appropriate reduction in antibody binding after solid-phase adsorptions of antibody with specific immobilized nucleoside conjugates. Disease-associated increases in serum IgG antibodies to cytidine and guanosine but not to adenosine or thymine-riboside occurred in patients with systemic lupus erythematosus (SLE). The epitope density of nucleosides in the conjugates and differences in the sensitivity of each nucleoside assay were not responsible for disease-associated IgG antinucleoside antibody responses. These findings support a possible pathogenic role for cytidine and guanosine as antigens or crossreactive antigenic determinants in some patients with SLE.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6603316     DOI: 10.1016/0090-1229(83)90092-2

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  4 in total

Review 1.  Origins of anti-DNA autoantibodies.

Authors:  R S Schwartz; B D Stollar
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

2.  Apheresis enhances the selective removal of antinuclear antibodies in systemic lupus erythematosus.

Authors:  K K Colburn; G A Gusewitch; B S Statian Pooprasert; R H Weisbart
Journal:  Clin Rheumatol       Date:  1990-12       Impact factor: 2.980

Review 3.  Drug-induced rheumatic syndromes. Diagnosis, clinical features and management.

Authors:  M G Cohen; M V Prowse
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 May-Jun

4.  Characterization of a human monoclonal IgM with antibody activity to dsDNA.

Authors:  J P Fermand; F Danon; J C Brouet
Journal:  Clin Exp Immunol       Date:  1985-02       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.